CJC-1295 + Ipamorelin 10 mg (5 mg + 5 mg)

About CJC-1295 + Ipamorelin

The CJC-1295 in this vial is the 29-amino-acid active segment of human GHRH with four amino acids replaced, at positions 2, 8, 15 and 27; a 2026 review says the changes make it harder for enzymes to break down.¹³ Ipamorelin, first described in 1998, is a five-amino-acid peptide that activates the ghrelin receptor (GHSR-1a).⁵³ Off-label fitness use pairs them to amplify growth hormone release through two receptors, a rationale a 2026 review calls largely anecdotal.³

This page lists CJC-1295 + Ipamorelin for sale as one 10 mg (5 mg + 5 mg) research vial, and the selector shows the CJC-1295 + Ipamorelin price and stock for each shipping origin.

The synergy idea comes from other peptides: in a 1990 study of 18 healthy men, low doses of GHRP-6 given with GHRH released growth hormone synergistically.⁹ No trial of CJC-1295 with ipamorelin has been published or registered, and FDA found no human study of the no-DAC form.¹⁵¹⁶¹ Side effects, study doses and the full source review: What is CJC-1295 + Ipamorelin?

Research highlights

• Ipamorelin in pigs (1998): ACTH and cortisol rose no more than with GHRH, even at over 200 times its half-maximal growth hormone dose; GHRP-6 and GHRP-2 raised both.⁵
• Ipamorelin in healthy men (1999, 8 per dose level): one 15-minute IV infusion gave a single growth hormone peak at about 40 minutes, and the half-life was about 2 hours.¹⁰
• Ipamorelin after bowel surgery (phase 2, 114 adults analyzed, 2014): IV dosing did not significantly speed the first tolerated meal (median 25.3 vs 32.6 hours, p = 0.15).¹¹
• CJC-1295 with DAC, a different form (2006, healthy adults): one injection raised mean growth hormone 2- to 10-fold for at least 6 days and IGF-1 1.5- to 3-fold for 9 to 11 days, results FDA says cannot be extrapolated to the no-DAC form.¹²¹
• Ipamorelin in female rats (1999): 15 days of injections sped long-bone growth, more at higher doses.¹³
• Ipamorelin in mice (2001): twice-daily injections raised fat pad weight relative to body weight, by routes the authors judged independent of growth hormone.¹⁴
• The blend: PubMed and ClinicalTrials.gov listed no clinical trial of it as of October 2026.¹⁵¹⁶

Regulatory status

Neither peptide is FDA-approved or has a USP or NF monograph, and no form of either is part of an approved drug.¹² FDA's Pharmacy Compounding Advisory Committee voted 13 to 0 against adding CJC-1295 free base, the no-DAC peptide, to the 503A bulks list on December 4, 2024, and 12 to 0, with 1 abstention, against each form of ipamorelin on October 29, 2024.¹⁷¹⁸ Ipamorelin acetate remains in FDA's category 2 for outsourcing facilities, meaning it may present significant safety risks.¹⁹ WADA bans both in and out of competition (class S2).²⁰ Every vial is labeled: For research use only. Not for human or veterinary use.

Handling and storage

FDA describes CJC-1295 free base as only slightly soluble in water but soluble in 1% acetic acid.¹ Ipamorelin acetate dissolves in water at 5 mg/mL; the free base reaches only 0.0032 mg/mL.² Which salt this vial holds is not stated, so these figures cannot predict how it dissolves. FDA notes that shifts in pH, heat or concentration can make such peptides clump and degrade.¹ Compounded CJC-1295 and ipamorelin injections have been recalled over unassured sterility, so sterile technique matters.²¹ Lab steps are in the reconstitution guide, and the reconstitution calculator turns a diluent volume into a concentration.